Evaluation of Cuprimine® and Syprine® for Decorporation of Radioisotopes of Cesium, Cobalt, Iridium, and Strontium
Cuprimine and Syprine are therapeutics approved by FDA to treat copper overload in Wilson Disease (a genetic defect in copper transport) by chelation and accelerated excretion of internally deposited copper. These oral therapeutics are based on respective active ingredients D-penicillamine (DPA) and N,N'-bis (2-aminoethyl)-1,2-ethanediamine dihydrochloride (Trien). Cuprimine is considered the primary treatment, although physicians increasingly are turning to Syprine as first-line therapy. Both drugs exhibit oral systemic activity and low toxicity; their biological effects and safety are established. The literature reports that these agents exhibit high affinity for a range of transition and f-metals and metalloids in vitro. Our previous in vivo studies using a rodent animal model established the decorporation potential of Cuprimine and Syprine for cobalt-60 and polonium-210 (Levitskaia et al 2010a). Currently we are expanding these studies to evaluate in vivo decorporation efficacy of these drugs for several additional radionuclides. In this paper, we discuss results of this investigation using gamma-emitting radionuclides including cesium-137 (137Cs), cobalt-60 (60Co), iridium-192 (192Ir), and strontium-85 (85Sr). Short-term 48 hr pilot studies were undertaken to evaluate DPA and Trien for their in vivo decorporation potency using male Wistar-Han rats. In these studies, radionuclide solution was administered to animals by IV injection, followed by a single IV dose of either DPA or Trien. Control animals received the radionuclide alone. Results show highly effective decorporation of 60Co by DPA. DPA and Trien were modestly effective in decorporation 137Cs and 85Sr, respectively. Based on these promising findings, further studies to evaluate the dose-response pharmacokinetic profiles for decorporation are warranted.
- Research Organization:
- Pacific Northwest National Lab. (PNNL), Richland, WA (United States)
- Sponsoring Organization:
- USDOE
- DOE Contract Number:
- AC05-76RL01830
- OSTI ID:
- 1019191
- Report Number(s):
- PNNL-SA-75291; HLTPAO; 400403909; TRN: US201114%%676
- Journal Information:
- Health Physics, 101(2):118-127, Vol. 101, Issue 2; ISSN 0017-9078
- Country of Publication:
- United States
- Language:
- English
Similar Records
In Vitro and In Vivo Evaluation of a Novel Ferrocyanide Functionalized Nanopourous Silica Decorporation Agent for Cesium in Rats
Investigation of Chitosan for Decorporation of 60Co in the Rat
Related Subjects
99 GENERAL AND MISCELLANEOUS//MATHEMATICS, COMPUTING, AND INFORMATION SCIENCE
ANIMALS
BIOLOGICAL EFFECTS
CESIUM
CESIUM 137
COBALT
COBALT 60
COPPER
DEFECTS
DISEASES
EXCRETION
GENETICS
IN VITRO
IN VIVO
IRIDIUM
IRIDIUM 192
POLONIUM 210
RADIOISOTOPES
SEMIMETALS
STRONTIUM
STRONTIUM 85
TOXICITY